D. Boral Capital Reiterates “Buy” Rating for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $33.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 45.31% from the company’s previous close.

A number of other brokerages also recently commented on URGN. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Urogen Pharma Stock Down 3.0%

NASDAQ:URGN opened at $22.71 on Monday. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The company has a fifty day simple moving average of $23.52 and a two-hundred day simple moving average of $19.59. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -6.56 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. The company had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. On average, analysts expect that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity at Urogen Pharma

In related news, CFO Chris Degnan sold 2,203 shares of the stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the transaction, the chief financial officer directly owned 2,280 shares of the company’s stock, valued at $38,418. This trade represents a 49.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the insider owned 139,025 shares in the company, valued at $3,475,625. This represents a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

Several hedge funds have recently made changes to their positions in the company. CWM LLC boosted its position in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after purchasing an additional 650 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Urogen Pharma by 9.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after buying an additional 797 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after acquiring an additional 1,653 shares during the period. Main Street Financial Solutions LLC grew its position in shares of Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after acquiring an additional 1,968 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.